Selected Drugs Clear All
MultiCheck Results
- 0
Interaction
Additional Considerations |
||
|
talquetamab
|
||
|
caution advised with narrow therapeutic index drugs metabolized by CYP450 liver enzymes, especially at initiation and up to 14 days after 1st tx dose or during/after CRS; talquetamab may transiently increase cytokine release leading to suppression of CYP450 metabolic function, causing incr. levels of concomitant drugs, risk of adverse effects |
||